SG11201805141QA - Compositions and methods for detecting and treating gastric cancer - Google Patents
Compositions and methods for detecting and treating gastric cancerInfo
- Publication number
- SG11201805141QA SG11201805141QA SG11201805141QA SG11201805141QA SG11201805141QA SG 11201805141Q A SG11201805141Q A SG 11201805141QA SG 11201805141Q A SG11201805141Q A SG 11201805141QA SG 11201805141Q A SG11201805141Q A SG 11201805141QA SG 11201805141Q A SG11201805141Q A SG 11201805141QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- methods
- gastric cancer
- compositions
- pct
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15307191 | 2015-12-31 | ||
EP16305131 | 2016-02-05 | ||
PCT/EP2017/050036 WO2017114975A1 (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating gastric cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805141QA true SG11201805141QA (en) | 2018-07-30 |
Family
ID=57821945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805141QA SG11201805141QA (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating gastric cancer |
Country Status (12)
Country | Link |
---|---|
US (1) | US20190011449A1 (zh) |
EP (2) | EP3397966B1 (zh) |
JP (3) | JP6909795B2 (zh) |
KR (2) | KR102477179B1 (zh) |
CN (1) | CN108700588A (zh) |
AU (2) | AU2017204685B2 (zh) |
BR (1) | BR112018013268A2 (zh) |
CA (2) | CA3193501A1 (zh) |
EA (1) | EA037027B1 (zh) |
ES (1) | ES2899360T3 (zh) |
SG (1) | SG11201805141QA (zh) |
WO (1) | WO2017114975A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019110662A1 (en) * | 2017-12-05 | 2019-06-13 | Progastrine Et Cancers S.À R.L. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
CN112004560A (zh) | 2017-12-08 | 2020-11-27 | Ecs生物识别系统有限公司 | 癌症诊断中的放射性标记的前胃液素 |
TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ecs前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
EP3759492A1 (en) | 2018-02-27 | 2021-01-06 | ECS-Progastrin SA | Progastrin as a biomarker for immunotherapy |
KR102379022B1 (ko) | 2019-05-24 | 2022-03-28 | 주식회사 엠디헬스케어 | qPCR 분석을 통한 위암 진단방법 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
PL193780B1 (pl) | 1997-04-14 | 2007-03-30 | Micromet Ag | Sposób wytwarzania receptora przeciw ludzkim antygenom, ludzkie przeciwciało i środek farmaceutyczny |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
FI20011908A (fi) * | 2001-09-28 | 2003-03-29 | Biohit Oyj | Menetelmä vatsasyövän osoittamiseksi |
JP2008513536A (ja) | 2004-09-22 | 2008-05-01 | レセプター バイオロジックス インコーポレイテッド | プロガストリンに対するモノクローナル抗体 |
WO2008076454A1 (en) * | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
SG10201704933PA (en) * | 2009-10-16 | 2017-07-28 | Inst Nat De La Sante Et De La Rech Medicale (Inserm) | Monoclonal antibodies to progastrin and their uses |
US9487582B2 (en) | 2010-01-08 | 2016-11-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for treating pancreatic cancer |
US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
CN101797382B (zh) * | 2010-03-03 | 2013-11-20 | 戚胜美 | 抗人前胃液素多肽免疫组合物 |
US8674064B2 (en) * | 2010-03-03 | 2014-03-18 | Onkologix Ltd | Immunogenic compositions against human progastrin peptides |
KR101570404B1 (ko) | 2010-03-24 | 2015-11-20 | 르 라보레또레 쎄르비에르 | 결장직장암 및 위창자암의 예방 |
KR101576174B1 (ko) | 2010-07-26 | 2015-12-09 | 르 라보레또레 쎄르비에르 | 간암 요법을 위한 방법 및 조성물 |
-
2017
- 2017-01-02 US US16/067,176 patent/US20190011449A1/en active Pending
- 2017-01-02 CA CA3193501A patent/CA3193501A1/en active Pending
- 2017-01-02 KR KR1020227022681A patent/KR102477179B1/ko active IP Right Grant
- 2017-01-02 EP EP17700482.7A patent/EP3397966B1/en active Active
- 2017-01-02 SG SG11201805141QA patent/SG11201805141QA/en unknown
- 2017-01-02 AU AU2017204685A patent/AU2017204685B2/en active Active
- 2017-01-02 KR KR1020187019707A patent/KR102428255B1/ko active IP Right Grant
- 2017-01-02 WO PCT/EP2017/050036 patent/WO2017114975A1/en active Application Filing
- 2017-01-02 JP JP2018534924A patent/JP6909795B2/ja active Active
- 2017-01-02 EA EA201891528A patent/EA037027B1/ru unknown
- 2017-01-02 EP EP21199550.1A patent/EP3954998A1/en active Pending
- 2017-01-02 BR BR112018013268A patent/BR112018013268A2/pt not_active IP Right Cessation
- 2017-01-02 ES ES17700482T patent/ES2899360T3/es active Active
- 2017-01-02 CA CA3009740A patent/CA3009740A1/en active Pending
- 2017-01-02 CN CN201780013849.4A patent/CN108700588A/zh active Pending
-
2021
- 2021-07-02 JP JP2021110785A patent/JP7478708B2/ja active Active
-
2022
- 2022-11-02 AU AU2022263503A patent/AU2022263503A1/en active Pending
-
2024
- 2024-01-19 JP JP2024006496A patent/JP2024041982A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
KR102428255B1 (ko) | 2022-08-03 |
JP2024041982A (ja) | 2024-03-27 |
US20190011449A1 (en) | 2019-01-10 |
EA201891528A1 (ru) | 2019-01-31 |
AU2017204685B2 (en) | 2022-10-13 |
KR20180105642A (ko) | 2018-09-28 |
CA3009740A1 (en) | 2017-07-06 |
AU2017204685A1 (en) | 2018-07-12 |
EP3397966A1 (en) | 2018-11-07 |
ES2899360T3 (es) | 2022-03-11 |
JP6909795B2 (ja) | 2021-07-28 |
BR112018013268A2 (pt) | 2018-12-11 |
JP2019505784A (ja) | 2019-02-28 |
EP3954998A1 (en) | 2022-02-16 |
AU2022263503A1 (en) | 2022-12-08 |
JP7478708B2 (ja) | 2024-05-07 |
WO2017114975A1 (en) | 2017-07-06 |
EA037027B1 (ru) | 2021-01-27 |
CN108700588A (zh) | 2018-10-23 |
KR102477179B1 (ko) | 2022-12-13 |
EP3397966B1 (en) | 2021-09-29 |
JP2021167831A (ja) | 2021-10-21 |
CA3193501A1 (en) | 2017-07-06 |
KR20220100099A (ko) | 2022-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201805263TA (en) | Compositions and methods for detecting and treating esophageal cancer | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201805141QA (en) | Compositions and methods for detecting and treating gastric cancer | |
SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201908998XA (en) | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201808108XA (en) | Synthesis of indazoles | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
SG11201908888VA (en) | Compositions and methods for treating lung cancer | |
SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
SG11201805605TA (en) | Compositions and methods for detecting and treating ovarian cancer | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201907693VA (en) | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof |